<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02990156</url>
  </required_header>
  <id_info>
    <org_study_id>2016-Nemo-01-A</org_study_id>
    <nct_id>NCT02990156</nct_id>
  </id_info>
  <brief_title>CATCH [Short Name for: Coil Application Trial in China]</brief_title>
  <acronym>CATCH</acronym>
  <official_title>Prospective, Randomized, Controlled, Open Label, All China, Multi-Center, Registration Trial of the MICROPORT NEUROTECH Coil Embolization System for the Traetment of Intracranial Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicroPort NeuroTech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MicroPort NeuroTech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The scope of this trial is the collection and analysis of effectiveness and safety endpoints,&#xD;
      related to the use of the MicroPort NeuroTech Coil Embolization System in the treatment of&#xD;
      intracranial aneurysms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A cerebral aneurysm (also known as an intracranial or intracerebral aneurysm) is a weak or&#xD;
      thin spot on a blood vessel in the brain that balloons out and fills and intermixes with&#xD;
      parent artery blood. Aneurysms can occur at any age. Global incidence varies by country, with&#xD;
      reports of prevalence ranging from 5.1 to 19.6 cases per 100,000 persons. With the&#xD;
      development of imaging technology and the greater attention paid by people to their overall&#xD;
      health,there will be more aneurysms be detected. The combination of sophisticated imaging&#xD;
      equipment, more frequent use of imaging in patients, and the aforementioned emphasis on&#xD;
      optimum health, has led to a greater proportion of asymptomatic aneurysms being discovered.&#xD;
&#xD;
      The most common type of aneurysms are saccular; and, aneurysms are more likely to occur in&#xD;
      women. The most devastating presentation of an intracranial aneurysm is subarachnoid&#xD;
      hemorrhage (SAH). It is estimated that, on average, five percent of the population is&#xD;
      afflicted and the incidence of aneurysm rupture (SAH) is between 6 and 9 per 1000 000&#xD;
      individuals . Mortality can approach 50%, with fewer than 60% of survivors returning to&#xD;
      independent living.&#xD;
&#xD;
      Invasive treatment of aneurysms began with an open surgical procedure referred to as&#xD;
      'surgical clipping'. This treatment was once considered the gold standard treatment for&#xD;
      aneurysms. The first neurovascular interventional medical device was the Guglielmi Detachable&#xD;
      Coil (GDC), which was developed and tested in the mid-1990s and was introduced by Dr. Guido&#xD;
      Guglielmi and Target Therapeutics, Fremont, California. These bare platinum coils were&#xD;
      electrolytically detached for placement in the aneurysm sac. It took approximately one decade&#xD;
      to prove coiling superiority over surgical clipping, after publication of the results of the&#xD;
      ISAT Study. Since that time, coils have become more sophisticated in makeup and conformation.&#xD;
      Coil use is also a mainstay for neurovascular procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2017</start_date>
  <completion_date type="Actual">November 21, 2020</completion_date>
  <primary_completion_date type="Actual">March 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Raymond Scale</measure>
    <time_frame>6 Months</time_frame>
    <description>For the MicroPort NeuroTech Coil Embolization System, this endpoint will be based upon the 6-month Core Lab identification of patients with &quot;Successful occlusion&quot; rate: % of subjects who at 6 months' post coiling, reported as a combination of Raymond 1 and Raymond 2 outcomes (95%-100%). The endpoint will be expressed as a percentage of all evaluable subjects with complete and nearly complete (95%-100%) occlusion in the context of the whole population of evaluable subjects (n/N).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>6 Months</time_frame>
    <description>6-months post-treatment &quot;Clinical Worsening&quot;, &quot;Clinical Worsening&quot; will be calculated as the percentage of subjects who meet the following condition: Final mRS score is more than 2 and is at least 1 point higher than the pre study measurement.&#xD;
For most subjects, this will be determined at the 6-months follow up visit. However, for those subjects whose trial participation is prematurely shortened, as a result of death (mRS will count as 6) or very serious device or procedure related debilitating injury, their final mRS determination will be counted, as the most recent score at the time of leaving the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">334</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <arm_group>
    <arm_group_label>Coil Embolization System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coil Embolization System,or deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame,and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control device from Medronic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control device from Medronic,include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils, which are manufactured by ev3 (Medtronic, Irvine, California, USA);</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coil Embolization System</intervention_name>
    <description>deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame, and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm. The intended use of the Microport NeuroTech Coil Embolization System is for the endovascular embolization of intracranial aneurysms.</description>
    <arm_group_label>Coil Embolization System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cotrol device from Medronic</intervention_name>
    <description>Control device from Medronic (include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils) are manufactured by ev3 (Medtronic, Irvine, California, USA);</description>
    <arm_group_label>Control device from Medronic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥18 years old and ≤80 years old at the time of signing the informed&#xD;
             consent;&#xD;
&#xD;
          2. Intracranial ruptured or unruptured, single, previously untreated, saccular aneurysm&#xD;
             diagnosed by CTA, MRA, DSA or other similar neuroimaging examination;&#xD;
&#xD;
          3. The maximum diameter of target aneurysm ≤24mm;&#xD;
&#xD;
          4. Baseline modified Rankin score (mRS) ≤2 points;&#xD;
&#xD;
          5. Baseline Hunt - Hess scores of patients with ruptured aneurysm ≤ Ⅲ;&#xD;
&#xD;
          6. The target aneurysm can be embolized in one operation;&#xD;
&#xD;
          7. The patient or the patient's guardian signs the informed consent voluntarily and is&#xD;
             willing to accept follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clear allergy, resistance or contraindication to antiplatelet drugs, anticoagulants,&#xD;
             contrast agents and/or anesthetics.&#xD;
&#xD;
          2. Definite allergy to platinum, tungsten and/or any substances of coils.&#xD;
&#xD;
          3. Subjects who are not suitable for anesthesia or endovascular treatment, such as those&#xD;
             suffering from severe respiratory system, liver and kidney diseases or coagulation&#xD;
             disorders (such as hemophilia).&#xD;
&#xD;
          4. Target aneurysm parent vessel stenosis ≥70%.&#xD;
&#xD;
          5. Anatomy not appropriate for endovascular treatment due to severe intracranial vessel&#xD;
             tortuosity or stenosis, or intracranial vasospasm not responsive to medical therapy.&#xD;
&#xD;
          6. The target aneurysm has previously received surgery or other endovascular treatment.&#xD;
&#xD;
          7. Ruptured aneurysm requiring stent-assisted embolization.&#xD;
&#xD;
          8. The target aneurysm is hemangioid aneurysm, dissected aneurysm, fusiform aneurysm,&#xD;
             infectious aneurysm, pseudoaneurysm, or arteriovenous malformation, or aneurysm&#xD;
             associated with Moyamoya disease.&#xD;
&#xD;
          9. Major surgery was performed within 30 days before enrollment, or surgery was planned&#xD;
             within 90 days after enrollment.&#xD;
&#xD;
         10. Patients with active infection at puncture point or other serious infection are not&#xD;
             suitable for endovascular treatment.&#xD;
&#xD;
         11. Illness with a potential risk of sudden death.&#xD;
&#xD;
         12. Subjects with intracranial space-occupying lesions (e.g., intracranial tumor, abscess,&#xD;
             etc.) or who are receiving radiotherapy for their head and neck.&#xD;
&#xD;
         13. Long-term treatment with anticoagulant drugs (such as warfarin) is required.&#xD;
&#xD;
         14. Having cognitive impairment, psychiatric disorder or other medical condition that may&#xD;
             affect the data evaluation or trial results.&#xD;
&#xD;
         15. Unable to understand the trial or has a record of noncompliance with medical advice.&#xD;
&#xD;
         16. Taking banned medicine.&#xD;
&#xD;
         17. Life expectancy less than 1 year, may not complete follow-up.&#xD;
&#xD;
         18. Women in pregnancy or lactation, or women with positive pregnancy test.&#xD;
&#xD;
         19. Subjects who are participating in clinical trials of other drugs or devices and have&#xD;
             not reached the end point of the trial, or are expected to participate in clinical&#xD;
             trials of other drugs or devices.&#xD;
&#xD;
         20. Investigators do not consider it appropriate to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianmin LIU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MicroportNT</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201318</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>April 7, 2022</last_update_submitted>
  <last_update_submitted_qc>April 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coils</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02990156
org study id: 2016-Nemo-01-A
nct id: NCT02990156
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The scope of this trial is the collection and analysis of effectiveness and safety endpoints,
      related to the use of the MicroPort NeuroTech Coil Embolization System in the treatment of
      intracranial aneurysms.
A cerebral aneurysm (also known as an intracranial or intracerebral aneurysm) is a weak or
      thin spot on a blood vessel in the brain that balloons out and fills and intermixes with
      parent artery blood. Aneurysms can occur at any age. Global incidence varies by country, with
      reports of prevalence ranging from 5.1 to 19.6 cases per 100,000 persons. With the
      development of imaging technology and the greater attention paid by people to their overall
      health,there will be more aneurysms be detected. The combination of sophisticated imaging
      equipment, more frequent use of imaging in patients, and the aforementioned emphasis on
      optimum health, has led to a greater proportion of asymptomatic aneurysms being discovered.

      The most common type of aneurysms are saccular; and, aneurysms are more likely to occur in
      women. The most devastating presentation of an intracranial aneurysm is subarachnoid
      hemorrhage (SAH). It is estimated that, on average, five percent of the population is
      afflicted and the incidence of aneurysm rupture (SAH) is between 6 and 9 per 1000 000
      individuals . Mortality can approach 50%, with fewer than 60% of survivors returning to
      independent living.

      Invasive treatment of aneurysms began with an open surgical procedure referred to as
      'surgical clipping'. This treatment was once considered the gold standard treatment for
      aneurysms. The first neurovascular interventional medical device was the Guglielmi Detachable
      Coil (GDC), which was developed and tested in the mid-1990s and was introduced by Dr. Guido
      Guglielmi and Target Therapeutics, Fremont, California. These bare platinum coils were
      electrolytically detached for placement in the aneurysm sac. It took approximately one decade
      to prove coiling superiority over surgical clipping, after publication of the results of the
      ISAT Study. Since that time, coils have become more sophisticated in makeup and conformation.
      Coil use is also a mainstay for neurovascular procedures.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Raymond Scale
time frame: 6 Months
description: For the MicroPort NeuroTech Coil Embolization System, this endpoint will be based upon the 6-month Core Lab identification of patients with "Successful occlusion" rate: % of subjects who at 6 months' post coiling, reported as a combination of Raymond 1 and Raymond 2 outcomes (95%-100%). The endpoint will be expressed as a percentage of all evaluable subjects with complete and nearly complete (95%-100%) occlusion in the context of the whole population of evaluable subjects (n/N).
measure: Modified Rankin Scale
time frame: 6 Months
description: 6-months post-treatment "Clinical Worsening", "Clinical Worsening" will be calculated as the percentage of subjects who meet the following condition: Final mRS score is more than 2 and is at least 1 point higher than the pre study measurement.
For most subjects, this will be determined at the 6-months follow up visit. However, for those subjects whose trial participation is prematurely shortened, as a result of death (mRS will count as 6) or very serious device or procedure related debilitating injury, their final mRS determination will be counted, as the most recent score at the time of leaving the study.
arm group label: Coil Embolization System
arm group type: Experimental
description: Coil Embolization System,or deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame,and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm.
arm group label: Control device from Medronic
arm group type: Active Comparator
description: Control device from Medronic,include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils, which are manufactured by ev3 (Medtronic, Irvine, California, USA);
intervention type: Device
intervention name: Coil Embolization System
description: deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame, and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm. The intended use of the Microport NeuroTech Coil Embolization System is for the endovascular embolization of intracranial aneurysms.
arm group label: Coil Embolization System
intervention type: Device
intervention name: Cotrol device from Medronic
description: Control device from Medronic (include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils) are manufactured by ev3 (Medtronic, Irvine, California, USA);
arm group label: Control device from Medronic
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
last name: Jianmin LIU, MD
role: Principal Investigator
affiliation: Changhai Hospital
facility: 
country: China
responsible party type: Sponsor
mesh term: Intracranial Aneurysm
mesh term: Aneurysm
sharing ipd: Undecided